"The recent rally in the Big Pharma stock can be attributed to the Trump administration announcing a plan for TrumpRx, which seeks to lower prescription costs for Americans, with Pfizer working in partnership with the federal government. This summer, the FDA announced it will only be recommending COVID-19 vaccines for seniors aged 65 and older and those with certain medical conditions, excluding healthy adults and children above a certain age from its recommendation."
"Pfizer continues to search for its footing in 2025 despite strong year-end 2024 results driven by stronger-than-expected sales from its COVID products, as well as its non-COVID products, such as Vyndaquel, Padcev and Eliquis. The 176-year-old Big Pharma mainstay has been at the forefront of its industry for several decades. Long known for its mass production of santonin (an antiparasitic drug), penicillin, and antibiotics, the latter part of the 20th century saw Pfizer invent Viagra (erectile dysfunction), Zoloft (anti-depressant)"
"Shares of Pfizer (NYSE: PFE) gained 10.02% over the past month after gaining 4.50% the month prior. The stock's year-to-date gain now stands at 2.50%. Over the past year, PFE has fallen by 3.76%. But over the past five years, the stock has let shareholders down despite paying a dividend with a current and substantial yield of 6.31%. Over that period, Pfizer has fallen 20.85%, and since its all-time high on Dec. 17, 2021, shares of PFE are down more than 54%."
Pfizer shares posted recent monthly gains but show a modest 2.50% year-to-date increase and are down 3.76% over the past year. The TrumpRx plan and partnership with the federal government helped fuel a rally, while the FDA narrowing COVID-19 vaccine recommendations limits potential market exposure. Pfizer’s COVID franchise, including Paxlovid and Comirnaty, generated $11.1 billion in combined 2024 revenue, supporting year-end results alongside non-COVID drugs like Vyndaquel, Padcev and Eliquis. The company carries a 6.31% dividend yield, yet shares have declined about 20.85% over five years and more than 54% since late 2021.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]